20 citations
,
May 2018 in “The Journal of Urology” This study concluded that 5α-reductase inhibitors were associated with improved survival in men with bladder cancer, while α-blockers showed no effect.
3 citations
,
March 2018 in “European Urology Supplements” This study found that Finnish men using 5-alpha-reductase inhibitors before or after bladder cancer diagnosis had improved disease-specific survival compared to non-users, suggesting potential benefits of the treatment.
3 citations
,
July 2014 in “Indian Journal of Surgery” Sex hormones might influence bladder cancer development, and aromatase inhibitors could increase risk in postmenopausal women.
1 citations
,
May 2023 in “Jurnal Kedokteran Diponegoro” This study examined the most common chemotherapy side effects among patients with prostate, bladder, and testicular cancer, noting hair loss, fatigue, and decreased appetite as frequent symptoms.
11 citations
,
November 2022 in “Frontiers in Oncology” This study conducted a bibliometric analysis of non-muscle invasive bladder cancer research, finding increased publications over two decades, with leading contributions from the United States and European institutions.